Acquired drug resistance by Mycobacterium tuberculosis (MTB) may result in treatment
failure and death. Bedaquiline was recently approved for the treatment of multidrug-resistant …

Treatment of multidrug-resistant tuberculosis (MDR-TB) is hindered by limited efficacy and
significant toxicity of second-line drugs. The need for new therapeutic options is critical to …

Purpose The history and prevalence of tuberculosis and the role of bedaquiline in multidrug-
resistant (MDR) tuberculosis are reviewed. Summary Tuberculosis continues to cause …

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis
(MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients …

Bedaquiline is a diarylquinoline antitubercular drug with a novel mechanism of action
against M ycobacterium tuberculosis. Bedaquiline works by inhibiting bacterial adenosine …

The 2-year follow-up results for a randomized placebo-controlled study of 47 patients with
multidrug-resistant pulmonary tuberculosis treated with either the new diarylquinoline …

Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial …

Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial
limitations, in terms of their effectiveness, side-effect profile, and complexity of …

Abstract Background In 2012, the Food and Drug Administration approved use of
bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis …

Background The emergence of drug resistance is a major threat to global tuberculosis (TB)
care and control. The World Health Organization (WHO) estimates that up to half a million …